About: Intrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Intrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Intrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories
Creator	Estella, Ángel Fontaiña, Jareño, Antonio Perez-Bello, Luis
source	PMC
abstract	BACKGROUND: Diffuse alveolar haemorrhage (DAH) is a serious pulmonary complication characterised by a high mortality rate and the absence of specific treatment. The intrapulmonary administration of activated recombinant factor VII (rFVIIa) in DAH was recently published in six patients by Heslet et al with an efficient hemostatic effect. We describe two cases of DAH treated with intrapulmonary rFVIIa. METHODS: Two cases of DAH were admitted to the ICU after presenting abrupt desaturation, tachypnea, cough and haemoptysis, requiring orotracheal intubation and mechanical ventilation. The diagnosis was achieved by the bloody return during the bronchoalveolar lavage, during the procedure rFVIIa (50 μg/Kg in 50 ml of isotonic saline) was administered via the bronchoscope. RESULTS: Immediate cessation of bleeding was observed. Prior to intrapulmonary administration of rFVIIa, the FiO(2 )was 1, which was reduced to 0.4 24 hours later. Following the procedure, the haemostatic effect made blood transfusion superfluous. No thrombotic complications associated with administration of the drug were observed. After the intervention both cases progressed fast and was discharged from the ICU with no further episodes of bleeding. CONCLUSION: 1. Local intrabronchial deposition of DAH with rFVIIa has been shown to be effective in controlling life-threatening DAH. 2. In the case described above, no thrombotic complications were observed following the intrapulmonary administration of rFVIIa.
has issue date	2008-09-12(xsd:dateTime)
bibo:doi	10.1186/1757-1626-1-150
bibo:pmid	18789132
has license	cc-by
sha1sum (hex)	559e8ed0debec62db69c8a6b94e5e0548efa32f3
schema:url	https://doi.org/10.1186/1757-1626-1-150
resource representing a document's title	Intrapulmonary administration of recombinant activated factor VII in diffuse alveolar haemorrhage: a report of two case stories
has PubMed Central identifier	PMC2551590
has PubMed identifier	18789132
schema:publication	Cases J
resource representing a document's body	covid:559e8ed0debec62db69c8a6b94e5e0548efa32f3#body_text
is schema:about of	named entity 'factor VII' named entity 'published' named entity 'case' named entity 'PUBLISHED' named entity 'RECENTLY' named entity 'HEMOSTATIC' named entity 'REPORT' named entity 'DIFFUSE ALVEOLAR HAEMORRHAGE' named entity 'administration' named entity 'describe' named entity 'hemostatic' named entity 'alveolar' named entity 'oxygen' named entity 'cough' named entity 'acute promyelocytic leukaemia' named entity 'endothelium' named entity 'orotracheal intubation' named entity 'haemorrhages' named entity 'tissue factor' named entity 'haemoptysis' named entity 'Bronchoalveolar lavage' named entity 'critically ill patients' named entity 'drug abuse' named entity 'lungs' named entity 'rFVIIa' named entity 'bone-marrow transplant' named entity 'haemophilia' named entity 'scientific evidence' named entity 'aspirin' named entity 'respiratory failure' named entity 'hypoxemic' named entity 'blood transfusion' named entity 'rFVIIa' named entity 'cough' named entity 'Haemoglobin' named entity 'reinfarction' named entity 'myocardial infarction' named entity 'Recombinant' named entity 'rFVIIa' named entity 'weaning' named entity 'thrombotic complications' named entity 'platelets' named entity 'mortality rate' named entity 'haemorrhagic' named entity 'haemoptysis' named entity 'Systemic administration' named entity 'muscular weakness' named entity 'rFVIIa' named entity 'Novoseven' named entity 'arteriovenous fistula' named entity 'rFVIIa' named entity 'X-ray' named entity 'haemoptysis' named entity 'HIV infection' named entity 'thrombin' named entity 'mechanical ventilation' named entity 'thrombolysis' named entity 'mechanical ventilation' named entity 'Systemic administration' named entity 'haemoptysis' named entity 'coagulopathies' named entity 'retrospective study' named entity 'HIV' named entity 'mechanical ventilation' named entity 'thrombogenic' named entity 'life-threatening' named entity 'thrombogenic' named entity 'hypoxemic' named entity 'mechanical ventilation' named entity 'low molecular weight heparin' named entity 'rFVIIa' named entity 'rFVIIa' named entity 'intubation' named entity 'orotracheal intubation' named entity 'thromboembolic events' named entity 'alveolar' named entity 'hepatitis' named entity 'haematological'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software